BioSpace News Archive

Akero Therapeutics, Inc. (Nasdaq: AKRO), today announced that members of the management team will participate in a fireside chat at the Jefferies Virtual Healthcare Conference at 10:30 a.m. ET on Tuesday, June 2, 2020.

Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, announced that Eiger management will present a corporate update at the Jefferies Virtual Healthcare Conference on June 4, 2020 from 9:30-9:55 PM ET.

Medpace Holdings, Inc. announced that it will present at the following two investor conferences in June 2020

Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined the Company’s Board of Directors

Alpine Immune Sciences, Inc., a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, announced its participation in an analyst-led fireside chat at the Jefferies Virtual Global Healthcare Conference on Tuesday, June 2, at 10:00 a.m. ET.

Neurotrope, Inc. (Nasdaq: NTRP) today announced that it will host an investor conference call and webcast to give an update on Bryostatin and the recently proposed merger between Neurotrope and Metuchen Pharmaceuticals, L.L.C. to form Petros Pharmaceuticals, Inc.

Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2020 Jefferies Virtual Healthcare Conference as follows

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results from the ALLO-501 ALPHA Phase 1 trial in relapsed/refractory non-Hodgkin lymphoma on May 29, 2020 via a live webinar at 5:30 AM Pacific Time/8:30 AM Eastern Time.

Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the ASCO20 Virtual Scientific Program on Friday, May 29, at 1:00 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen,

-- Improvements in both serum liver enzymes and liver imaging -- Improvement in serum lipid profile -- DUR-928 was well tolerated with no significant adverse events -- Promising data support further development of DUR-928 in NASH